Treatment of canine leishmaniasis: long term molecular and serological observations

• Autorzy: Arti G. , Nardoni S. , Papini R. , Mugnaini L. , Giannetti G. , Bizzeti M. , Fanetti N. , Mancianti F.
• Języki publikacji: EN

Abstrakty

EN

The aim of the present paper was to evaluate the anti-Leishmania activity of 3 different protocols of treatment (miltefosine plus allopurinol, difloxacin cloridrate plus metronidazole and meglumine antimoniate plus allopurinol) in 42 dogs naturally infected by L. infantum, during a 24-months parasitological and clinical follow-up. Our results suggest that, apart from miltefosine, the other two therapeutic regimens could be evaluated to treat animals with canL in medium-endemicity areas.

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2013
• Tom: 69
• Numer: 02
• Opis fizyczny: p.109-111,ref.

Twórcy

autor

Arti G.

• Dipartimento di Scienze Veterinarie Universita di Pisa, Italy

autor

Nardoni S.

• Dipartimento di Scienze Veterinarie Universita di Pisa, Italy

autor

Papini R.

• Dipartimento di Scienze Veterinarie Universita di Pisa, Italy

autor

Mugnaini L.

• Dipartimento di Scienze Veterinarie Universita di Pisa, Italy

autor

Giannetti G.

autor

Bizzeti M.

• Dipartimento di Scienze Veterinarie Universita di Pisa, Italy

autor

Fanetti N.

• Dipartimento di Scienze Veterinarie Universita di Pisa, Italy

autor

Mancianti F.

• Dipartimento di Scienze Veterinarie Universita di Pisa, Italy

Bibliografia

• 1.Baneth G., Shaw S. E.: Chemotherapy of canine leishmaniosis. Vet. Parasitol. 2002, 106, 315-324.
• 2.Bern C., Adler-Moore J., Berenguer J., Boelaert M., den Boer M., Davidson R. N., Figueras C., Gradoni L., Kafetzis D. A., Ritmeijer K., Rosenthal E., Royce C., Russo R., Sundar S., Alvar J.: Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis Rev. Anti-Inf. Ag. CID 2006, 43, 919-924.
• 3.Bianciardi P., Fasanella A., Foglia Manzillo V., Trotta T., Pagano A., Sorino S., Gradoni L., Oliva G.: The efficacy of enrofloxacin, alone or combined with metronidazole, in the therapy of canine leishmaniasis. Parasitol Res. 2004, 93, 486-492.
• 4.Cojean S., Houzé S., Haouchine D., Huteau F., Lariven S., Hubert V., Michard F., Bories C., Pratlong F., Le Bras J., Loiseau P. M., Matheron S.: Leishmania resistance to miltefosine associated with genetic marker. Emerg. Infect. Dis. 2012, 18, 704-706.
• 5.Costa C. H. N.: How effective is dog culling in controlling zoonotic visceral leishmaniasis? A critical evaluation of the science, politics and ethics behind this public health policy. Rev. Soc. Bras. Med. Trop. 2011, 44, 232-242.
• 6.Duprey Z., Steurer F., Rooney J., Kirchhoff L., Jackson J., Rowton E., Schantz P.: Canine visceral leishmaniasis, United States and Canada, 2000-2003. Emerging Infect. Dis. 2006, 12, 440-446.
• 7.Faraut-Gambarelli F., Piarroux R., Deniau M., Giusiano B., Marty P., Michel G., Faugère B., Dumon H.: In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob. Agents Chemother. 1997, 41, 827-830.
• 8.Farca A. M., Miniscalco B., Badino P., Odore R., Monticelli P., Trisciuoglio A., Ferroglio E.: Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum. Parasitol. Res. 2012, 110, 2509-2513.
• 9.Gramiccia M., Gradoni L., Orsini S.: Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann Trop Med Parasitol. 1992, 8, 613-620.
• 10.João A., Pereira M. A., Cortes S., Santos-Gomes G. M.: Canine leishmaniasis chemotherapy: dog’s clinical condition and risk of Leishmania transmission. J. Vet. Med. A Physiol. Pathol. Clin. Med. 2006, 53, 540-545.
• 11.Maltezou H. C.: Drug resistance in visceral leishmaniasis. J. Biomed. Biotechnol. 2010; Article ID 617521, doi:10.1155/2010/617521.
• 12.Mancianti F., Meciani N.: Specific serodiagnosis of canine leishmaniasis by indirect immunofluoresence, indirect hemagglutination and counterimmunoelectrophoresis. Am. J. Vet. Res. 1988, 49, 1409-1411.
• 13.Manna L., Vitale F., Reale S., Picillo E., Neglia G., Vescio F., Gravino A. E.: Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis. Vet. J. 2009, 182, 441-445.
• 14.Miró G., Gálvez R., Fraile C., Descalzo M. A., Molina R.: Infectivity to Phlebotomus perniciosus of dogs naturally parasitized with Leishmania infantum after different treatments. Parasit. Vectors 2011, 4, 52.
• 15.Miró G., Oliva G., Cruz I., Cañavate C., Mortarino M., Vischer C., Bianciardi P.: Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis. Vet. Dermatol. 2009, 20, 397-404.
• 16.Pérez-Victoria F. J., Sánchez-Cañete M. P., Seifert K., Croft S. L., Sundar S., Castanys S., Gamarro F.: Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist. Updat. 2006, 9, 26-39.
• 17.Ribeiro R. R., Moura E. P., Pimentel V. M., Sampaio W. M., Silva S. M., Schettini D. A., Alves C. F., Melo F. A., Tafuri W. L., Demicheli C., Melo M. N., Frézard F., Michalick M. S.: Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate. Antimicrob. Agents Chemother. 2008, 52, 2564-2572.
• 18.Rodgers M. R., Stephen J., Wirth D. F.: Amplification and diagnosis of leishmania. Exp. Parasitol. 1990, 71, 267-275.
• 19.Rougier S., Vouldoukis I., Fournel S., Pérès S., Woehrlé F.: Efficacy of different treatment regimens of marbofloxacin in canine visceral leishmaniosis: a pilot study. Vet. Parasitol. 2008, 153, 244-254.
• 20.Solano-Gallego L., Koutinas A., Miró G., Cardoso L., Pennisi M. G., Ferrer L., Bourdeau P., Oliva G., Baneth G.: Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis Vet. Parasitol. 2009, 165, 1-18.
• 21.Sundar S., Olliaro P. L.: Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther. Clin. Risk Manag. 2007, 3, 733-740.
• 22.Vouldoukis I., Rougier S., Dugas B., Pino P., Mazier D., Woehrlé F.: Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate. Vet. Parasitol. 2006, 135, 137-146.
• 23.Woerly V., Maynard L., Sanquer A., Eun H. M.: Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis Parasitol. Res. 2009, 105, 463-469.
• 24.World Health Organization. Control of the leishmaniasis. Report of a WHO Expert Committee. WHO Expert Committee on the Control of the Leishmaniases, World Health Organization, Geneva, Switzerland. 1990.

Uwagi

Rekord w opracowaniu